The development of an effective HIV vaccine remains an urgent public health need due to the high genetic variability and rapid mutation rates of the virus, which limit the generation of broadly ...

Billionaire Elon Musk's plundering of the US Agency for International Development (USAID) is already proving devastating for ...

Recombinant antibodies are invented antibodies formed by using recombinant DNA technology. While traditional monoclonal ...

Broadly neutralizing antibodies (bNAbs) were first discovered in the '90s when it was observed that HIV-infected individuals possessed antibodies that could recognize and neutralize different subtypes ...

Health Minister Dr Atonio Lalabalavu has declared an outbreak of HIV cases in the country. He says between January and September 2024 Fiji recorded 1093 cases. He revealed the figures during the ...

ACACIA is a phase 2, double-blind, randomized study evaluating the safety and virologic and immunologic effects of the two long-acting broadly neutralizing antibodies (bNAbs) 3BNC117-LS and 10-1074-LS ...

ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of the ACACIA study (Antiretrovirals ...

If future experiments show that that the antibodies are, indeed, unwanted, it could guide vaccine design strategies to minimize the immune complex response and improve the ability for vaccines to ...

Bimagrumab, LAE102, and Garetosmab are three monoclonal antibody medicines that target Activin. Bimagrumab, developed by Novartis, is a high-affinity antibody that targets Activin RIIB ...

"These antibodies actually make no direct contact ... response and improve the ability for vaccines to directly neutralize HIV. It also could lead to changes in HIV vaccine schedules, potentially ...